Nalaganje...
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called ho...
Shranjeno v:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3916637/ https://ncbi.nlm.nih.gov/pubmed/24516334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S41786 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|